Clinical trials for ER/PR positive breast cancer

Trial name

Title of clinical trial

Hyperlink

G1T38

A trial using a CDK 4/6 inhibitor in combination with fulvestrant in hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.
Open to men and women.

AIPAC

A study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 or placebo in addition to a standard chemotherapy treatment regimen of paclitaxel.
Open to women.

GSK525762

A study to evaluate the safety of GSK525762 when taken with fulvestrant in subjects with estrogen receptor positive breast cancer.
Open to women.

STEM

A trial assessing SFX-01 in combination with aromatase inhibitors (AIs), tamoxifen and fulvestrant in metastatic breast cancer.
Open to men & women.

CORE

A randomised controlled trial, which includes breast, prostate or non-small cell lung primary cancer and extra cranial oligometastases suitable for stereotactic body radiotherapy.

B-AHEAD 3

A randomised trial of intermittent energy restriction and resistance exercise in women receiving chemotherapy for advanced breast cancer.
Open to women.

PIPA

A study looking at taselisib and palbociclib for breast cancer with a mutation in the PIK3CA gene that has stopped responding to treatment.
Open to men & women.

Plasma Match

A trial carrying out plasma based molecular profiling of advanced breast cancer to inform therapeutic choices.
Open to women.